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In their Comment,1 Dana Yelin and 
colleagues highlight the persistent, 
heterogeneous, and recurring 
symptoms of long COVID. A Lancet 
Editorial2 asks for better research and 
care to avoid years of struggle for 
individuals with long COVID. We write 
following an international, multi-
stakeholder forum, in which peoples’ 
voices were central, to expand the call 
to action and to identify how we can 
prevent long COVID from becoming 
the long-lasting legacy of COVID-19.
On Dec 9–10, 2020, the International 
Severe Acute Respiratory and Emerging 
Infection Consortium (ISARIC), the 
Global Research Collaboration for 
Infectious Disease Preparedness 
(GloPID-R) research funders group, 
and Long COVID Support, a global 
patient group, held the Long COVID 
Forum (appendix pp 1–2). We brought 
together people living with long COVID, 
interdisciplinary researchers, funders, 
public health experts, and policy 
makers, including WHO, in a global 
public forum to identify research gaps 
to inform urgent long COVID research 
and support priorities.
Our discussions, introduced by 
WHO Director-General Tedros 
Adhanom Ghebreyesus, were built 
around three people-centred themes, 
identified by long COVID support 
groups: recognition, research, and 
rehabilitation. We heard from people 
living with long COVID from around 
the world, who asked: what is causing 
my illness? What can I do to recover? 
Why do I have long COVID when others 
recover quickly? How do I convince my 
doctor that what I am suffering from 
is real? How can others be prevented 
from getting long COVID? We explored 
existing evidence,3 including the 
recently funded research portfolio 
on long COVID that will contribute 
to the evidence body in the short to 
mid-term4 and updates from ongoing 
research from around the world. A 
complex, multifaceted condition 
involving a range of physical, cognitive, 
and psychological symptoms was 
described, affecting adults and children 
in different settings, with occupational, 
economic, and social implications. 
Such complexity requires a mult-
idisciplinary, globally coordinated 
approach that supports harmonised, 
large-scale studies that have the 
power to provide robust evidence to 
inform policy and patient-centred care 
and support to improve long COVID 
outcomes.
The structure of the forum facilitated 
the identification of research gaps 
(appendix p 3). The core message was 
the need to expand research beyond 
hospitalised patients to include those 
who experienced COVID-19 in the 
community, children, vulnerable 
commu nities, and resource-con-
strained populations to improve 
equity in access to research and reduce 
health inequalities.
CH is living with long COVID and is a founder of the 
Long Covid Support Group. JCS reports experiencing 
persisting symptoms of COVID-19, following 
suspected COVID-19 in March, 2020. All other 
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reinforcing the need for continuous 
measures to contain SARS-CoV-2 
spread, despite growing pandemic 
fatigue in the population,5 and 
to avoid potentially catastrophic 
COVID-19-related hospitalisations 
and deaths in the critical months 
ahead.
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CovMT also provides a timeline 
history of SARS-CoV-2 variants 
related to mutations in the RBD 
region of the spike protein. As of 
the end of January, 2021, the spread 
of N501Y, B.1.1.7 variants has been 
detected in SARS-CoV-2 isolate 
genomes from nearly 60 additional 
countries using CovMT (appendix). 
Nonsynonymous mutations in the 
RBD region have a high potential 
to be linked to increased binding 
efficiency, increased infectivity, and 
the potential to evade antibodies.2–4 
To track all similar variants, we 
ranked mutations in the RBD region 
based on their appearance in the 
number of isolate genomes in CovMT. 
The CovMT timeline (appendix) 
shows that N501Y, S477N, N439K, 
and L452R mutations can now 
be detected in more than 41 700, 
23 300, 9700, and 2000 isolates, 
respectively. An important RBD 
mutation, E484K, which probably 
allows the virus to evade existing 
antibodies,5 was originally recorded in 
Denmark during March, 2020, and is 
now on the rise in South Africa5 since 
October, 2020. More than 510 isolates 
show triple mutations (K417N, 
E484K, and N501Y, lineage B.1.351) 
in South Africa, with some isolates 
now detected in the UK and 22 other 
countries. We observed that the UK 
variant (B.1.1.7) has also acquired the 
E484K mutation (appendix). A more 
recent variant, P.1, with E484K and 
N501Y RBD mutations, appeared in 
four travellers arriving in Japan from 
Brazil on Jan 2, 2021. The P.1 variant 
now appears in six other countries. 
Timelines and lineage history of each 
of the top ten most common RBD 
mutations can be explored at CovMT.
With a particular focus on critical 
mutations in the RBD region of the 
spike protein, and with an option 
to seamlessly accrue the clinical 
metadata, including disease severity, 
we believe that CovMT will be useful 
for scientists, the general public, and 
authorities to explore country-specific 
information.
3 Michelen M, Manoharan L, Elkheir N, et al. 
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CovMT: an interactive 
SARS-CoV-2 mutation 
tracker, with a focus on 
critical variants
The number of confirmed SARS-CoV-2 
cases worldwide has now reached 
around 100 million, with 2·1 million 
reported deaths1 and more than 
450 000 SARS-CoV-2 genomes already 
sequenced. It is vital to keep track of 
mutations in the genome of SARS-
CoV-2, especially in the spike protein’s 
receptor binding domain (RBD) region, 
which could potentially impact disease 
severity and treatment strategies.2–4 In 
the wake of a recent increase in cases 
with a more infective variant featuring 
an RBD mutation (N501Y, B.1.1.7) 
in the UK, countries worldwide are 
concerned about the spread of this or 
similar variants. Increasing sequencing 
efforts and user-friendly mutation 
tracking systems are needed for timely 
tracking of SARS-CoV-2 variants.
We developed a COVID-19 virus 
mutation tracker system (CovMT; 
appendix) based on SARS-CoV-2 
isolate genomes deposited to GISAID 
to track the worldwide sequencing 
efforts and the evolution of the 
mutational landscape of this virus. 
CovMT, which is updated daily, 
summarises mutations from more 
than 450 000 isolates into groups 
of generic virus clades, lineages, 
and more specific mutation sets we 
call mutation fingerprints. These 
summaries, with metadata of location, 
date of sampling, and patient disease 
severity information, when available, 
at the continent and country levels, 
are accessible from the main page of 
the CovMT system (appendix). 
For CovMT see https://www.
cbrc.kaust.edu.sa/covmt
See Online for appendix
For GISAID see http://gisaid.org
Published Online 
February 8, 2021 
https://doi.org/10.1016/S1473-
3099(21)00078-5
This online publication has 
been corrected. The corrected 







Iran was among the first countries 
outside China to report a large 
out break of COVID-19, but the 
transmission dynamics across the 
country have largely remained 
unknown due to the scarcity of 
serological, epidemiological, and 
genomic data. One of the main barriers 
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